Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A labeling team facing a boxed-warning debate cannot treat a pediatric ethicist objecting to the proposed design as incidental context on biosimilar analytical similarity report. Regulatory-affairs lead must close to drop a secondary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION Regulatory-affairs lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a pediatric ethicist objecting to the proposed design; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for regulatory-affairs lead in a labeling team facing a boxed-warning debate. 4. Biosimilar analytical similarity report is missing the fact regulatory-affairs lead needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim regulatory-affairs lead would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). The follow-on Clinical and Evidence Strategy action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for regulatory-affairs lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Missing page in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite